Terms: = Ovarian cancer AND TP53, TRP53, 7157, ENSG00000141510, P04637, LFS1, P53 AND Treatment
980 results:
1. Comprehensive Analysis of Clinically Relevant Copy Number Alterations (CNAs) Using a 523-Gene Next-Generation Sequencing Panel and NxClinical Software in Solid Tumors.
Gupta V; Vashisht V; Vashisht A; Mondal AK; Alptekin A; Singh H; Kolhe R
Genes (Basel); 2024 Mar; 15(4):. PubMed ID: 38674331
[TBL] [Abstract] [Full Text] [Related]
2. The Predictive Role of Serum Lipid Levels, p53 and ki-67, According to Molecular Subtypes in Breast cancer: A Randomized Clinical Study.
Faur IF; Dobrescu A; Clim IA; Pasca P; Prodan-Barbulescu C; Tarta C; Neamtu AA; Brebu D; Neamtu C; Rosu M; Duta C; Clim A; Lazar G; Totolici B
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612725
[TBL] [Abstract] [Full Text] [Related]
3. Functional analysis and validation of oncodrive gene AP3S1 in ovarian cancer through filtering of mutation data from whole-exome sequencing.
Kong D; Wu Y; Liu Q; Huang C; Wang T; Huang Z; Gao Y; Li Y; Guo H
Eur J Med Res; 2024 Apr; 29(1):231. PubMed ID: 38609993
[TBL] [Abstract] [Full Text] [Related]
4. Human epidermal growth factor receptor-2 expression and subsequent dynamic changes in patients with ovarian cancer.
Kim YN; Chung YS; Park E; Lee ST; Lee JY
Sci Rep; 2024 Apr; 14(1):7992. PubMed ID: 38580676
[TBL] [Abstract] [Full Text] [Related]
5. Static magnetic field reduces cisplatin resistance via increasing apoptosis pathways and genotoxicity in cancer cell lines.
Zafari J; Rastegar-Pouyani N; Javani Jouni F; Najjar N; Azarshin SZ; Jafarzadeh E; Abdolmaleki P; Hoseini Shirazi F
Sci Rep; 2024 Mar; 14(1):5792. PubMed ID: 38461218
[TBL] [Abstract] [Full Text] [Related]
6. STEAP3 Affects ovarian cancer Progression by Regulating Ferroptosis through the p53/SLC7A11 Pathway.
Han Y; Fu L; Kong Y; Jiang C; Huang L; Zhang H
Mediators Inflamm; 2024; 2024():4048527. PubMed ID: 38440354
[TBL] [Abstract] [Full Text] [Related]
7. Paraptotic Cell Death as an Unprecedented Mode of Action Observed for New Bipyridine-Silver(I) Compounds Bearing Phosphane Coligands.
Teixeira RG; Stefanelli A; Pilon A; Warmers R; Fontrodona X; Romero I; Costa PJ; Villa de Brito MJ; Hudec X; Pirker C; Türck S; Antunes AMM; Kowol CR; Ott I; Brozovic A; Sombke A; Eckhard M; Tomaz AI; Heffeter P; Valente A
J Med Chem; 2024 Apr; 67(8):6081-6098. PubMed ID: 38401050
[TBL] [Abstract] [Full Text] [Related]
8. Developing Folate-Conjugated miR-34a Therapeutic for Prostate cancer: Challenges and Promises.
Li WJ; Wang Y; Liu X; Wu S; Wang M; Turowski SG; Spernyak JA; Tracz A; Abdelaal AM; Sudarshan K; Puzanov I; Chatta G; Kasinski AL; Tang DG
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396800
[TBL] [Abstract] [Full Text] [Related]
9. Complexity of the Genetic Background of Oncogenesis in ovarian cancer-Genetic Instability and Clinical Implications.
Murawski M; Jagodziński A; Bielawska-Pohl A; Klimczak A
Cells; 2024 Feb; 13(4):. PubMed ID: 38391958
[TBL] [Abstract] [Full Text] [Related]
10. CD47-a novel prognostic predicator in epithelial ovarian cancer and correlations with clinicopathological and gene mutation features.
Luo X; Mo J; Zhang M; Huang W; Bao Y; Zou R; Yao L; Yuan L
World J Surg Oncol; 2024 Feb; 22(1):44. PubMed ID: 38317230
[TBL] [Abstract] [Full Text] [Related]
11. BRCA1, BRCA2, and tp53 germline and somatic variants and clinicopathological characteristics of Brazilian patients with epithelial ovarian cancer.
Richau CS; Scherer NM; Matta BP; de Armas EM; de Barros Moreira FC; Bergmann A; Pereira Chaves CB; Boroni M; Dos Santos ACE; Moreira MAM
Cancer Med; 2024 Feb; 13(3):e6729. PubMed ID: 38308422
[TBL] [Abstract] [Full Text] [Related]
12. Integration of the Molecular Classification of Endometrial Carcinoma to Select Patients for Fertility Sparing Strategies.
Bani MA; Maulard A; Morice P; Chargari C; Genestie C
Anticancer Res; 2024 Feb; 44(2):445-452. PubMed ID: 38307584
[TBL] [Abstract] [Full Text] [Related]
13. Human Fallopian Tube-Derived Organoids with tp53 and RAD51D Mutations Recapitulate an Early Stage High-Grade Serous ovarian cancer Phenotype In Vitro.
Dai Y; Xu J; Gong X; Wei J; Gao Y; Chai R; Lu C; Zhao B; Kang Y
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38255960
[TBL] [Abstract] [Full Text] [Related]
14. CircNUP50 is a novel therapeutic target that promotes cisplatin resistance in ovarian cancer by modulating p53 ubiquitination.
Zhu Y; Liang L; Zhao Y; Li J; Zeng J; Yuan Y; Li N; Wu L
J Nanobiotechnology; 2024 Jan; 22(1):35. PubMed ID: 38243224
[TBL] [Abstract] [Full Text] [Related]
15. Predictive and prognostic biomarkers in female genital tract tumours: an update highlighting their clinical relevance and practical issues.
Wong RW; Cheung ANY
Pathology; 2024 Mar; 56(2):214-227. PubMed ID: 38212229
[TBL] [Abstract] [Full Text] [Related]
16. FGL2 promotes tumour growth and attenuates infiltration of activated immune cells in melanoma and ovarian cancer models.
Galpin KJC; Rodriguez GM; Maranda V; Cook DP; Macdonald E; Murshed H; Zhao S; McCloskey CW; Chruscinski A; Levy GA; Ardolino M; Vanderhyden BC
Sci Rep; 2024 Jan; 14(1):787. PubMed ID: 38191799
[TBL] [Abstract] [Full Text] [Related]
17. [News in breast oncology genetics for female and male population].
Taris N; Luporsi E; Osada M; Thiblet M; Mathelin C
Gynecol Obstet Fertil Senol; 2024 Mar; 52(3):149-157. PubMed ID: 38190969
[TBL] [Abstract] [Full Text] [Related]
18. A novel targeted NGS panel identifies numerous homologous recombination deficiency (HRD)-associated gene mutations in addition to known BRCA mutations.
Vogel A; Haupts A; Kloth M; Roth W; Hartmann N
Diagn Pathol; 2024 Jan; 19(1):9. PubMed ID: 38184614
[TBL] [Abstract] [Full Text] [Related]
19. Danggui Shaoyao San protects cyclophosphamide-induced premature ovarian failure by inhibiting apoptosis and oxidative stress through the regulation of the SIRT1/p53 signaling pathway.
Chen H; Zhang G; Peng Y; Wu Y; Han X; Xie L; Xu H; Chen G; Liu B; Xu T; Pang M; Hu C; Fan H; Bi Y; Hua Y; Zhou Y; Luo S
J Ethnopharmacol; 2024 Apr; 323():117718. PubMed ID: 38181933
[TBL] [Abstract] [Full Text] [Related]
20. Selectively targeting BCL6 using a small molecule inhibitor is a potential therapeutic strategy for ovarian cancer.
Wu M; Xie J; Xing Y; Zhang L; Chen H; Tang B; Zhou M; Lv S; Huang D; Jian S; Zhou C; Liu M; Guo W; Chen Y; Yi Z
Int J Biol Sci; 2024; 20(2):486-501. PubMed ID: 38169532
[TBL] [Abstract] [Full Text] [Related]
[Next]
